Epstein-Barr virus (EBV) reactivation and EBV-lymphoproliferative disease
| Parameter . | T-cell-depleted allo-SCT (n = 85) . | Unmanipulated allo-SCT (n = 65) . |
|---|---|---|
| No. of patients with EBV reactivation (%) | 46 (54) | 18 (28) |
| Time (d) to first EBV reactivation (median, range) | 58 (5-180) | 63 (2-107) |
| Maximum viral load (gEq/mL) of first EBV reactivation (median, range) | 535 (50-3 200 000) | 808 (55-540 000) |
| No. of patients (%) with recurrent EBV reactivation | 14 (16) | 2 (3) |
| No. of patients (%) with EBV-LPD | 10 (12) | — |
| Time (d) from SCT to EBV-LPD (median, range) | 87 (50-168) | — |
| Time (d) from first EBV reactivation to EBV-LPD (median, range) | 22 (13-120) | — |
| EBV-LPD viral load (gEq/mL, median, range) | 110 000 (1800-790 000) | — |
| Parameter . | T-cell-depleted allo-SCT (n = 85) . | Unmanipulated allo-SCT (n = 65) . |
|---|---|---|
| No. of patients with EBV reactivation (%) | 46 (54) | 18 (28) |
| Time (d) to first EBV reactivation (median, range) | 58 (5-180) | 63 (2-107) |
| Maximum viral load (gEq/mL) of first EBV reactivation (median, range) | 535 (50-3 200 000) | 808 (55-540 000) |
| No. of patients (%) with recurrent EBV reactivation | 14 (16) | 2 (3) |
| No. of patients (%) with EBV-LPD | 10 (12) | — |
| Time (d) from SCT to EBV-LPD (median, range) | 87 (50-168) | — |
| Time (d) from first EBV reactivation to EBV-LPD (median, range) | 22 (13-120) | — |
| EBV-LPD viral load (gEq/mL, median, range) | 110 000 (1800-790 000) | — |
gEq/mL indicates genome equivalents of EBV DNA/mL. Other abbreviations are explained in Table 1.